An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers
Stopped early · Phase 1/Phase 2
Conditions studied: Cancer
In brief
The purpose of this study is to investigate experimental medication BMS-986277 given alone and in combination with Nivolumab in patients with epithelial cancers.
Key facts
- Study ID
- NCT03363776
- Run by
- Bristol-Myers Squibb
- People needed
- 10
- Starts
- 2017-12-06
- Expected to finish
- 2019-11-22
- Last updated by the study team
- 2020-12-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histological or cytological confirmation of metastatic and/or unresectable metastatic colorectal, prostate, pancreatic, breast, ovarian, or urothelial carcinoma with measureable disease for solid tumors per RECIST v1.1 and for prostate carcinoma per PCWG3
- Presence of at least 2 lesions: at least one with measurable disease as defined by RECIST v1.1 for solid tumors and by PCWG3 for prostate carcinoma for response assessment; at least 1 lesion must be accessible for biopsy in addition to the target lesion
- Participants must have received, and then progressed or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting, if such a therapy exists, and have been considered for all other potentially efficacious therapies prior to enrollment
- ECOG performance status less than or equal to 2
You may not qualify if…
- Participants with active central nervous system (CNS) metastases, untreated CNS metastases, or with the CNS as the only site of disease
- Participants with carcinomatous meningitis
- Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study treatment
- Participants with active, known, or suspected autoimmune disease
- Other protocol defined inclusion/exclusion criteria could apply
Where it is running
- Sanford Research — Sioux Falls, South Dakota, United States
- Local Institution — Ottawa, Ontario, Canada
- Princess Margaret Cancer Centre — Toronto, Ontario, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.